Insulet presents 'promising' data from study of Omnipod Horizon system
Insulet announced additional promising data from the first feasibility study of the Omnipod Horizon Automated Glucose Control System hybrid closed-loop system. Initial results presented earlier this year demonstrated Insulet's personalized model predictive control algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose. New data revealed today at the American Diabetes Association 77th Scientific Sessions in San Diego demonstrated pediatric and adolescent populations experienced positive results consistent with the performance in the adult population, reinforcing Insulet's expectation of the many future benefits of the Omnipod Horizon. The 36-hour study included a modified version of Insulet's Omnipod System, a Dexcom continuous glucose sensor, and Insulet's personalized MPC algorithm with announced meals ranging from 30-90 grams of carbohydrates and limited physical activity. Overall, the study included 34 adults, 12 adolescents and 12 pediatric patients with type 1 diabetes. Key findings in the pediatric and adolescent patients included greater than 70% of time spent in the target blood glucose range overall and approximately 85% or greater time in the target range overnight. These initial results indicate that the algorithm performance can address the unique challenges faced by pediatric populations with high insulin sensitivity and adolescents who tend to be insulin resistant.